Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences in February and March:

• Oppenheimer 36th Annual Healthcare Life Sciences Conference
  • Dates: February 25-26, 2026
  • Location: Virtual

• Leerink Partners Global Healthcare Conference
  • Dates: March 8-11, 2026
  • Location: Miami, FL

• Stifel 2026 Virtual CNS Forum
  • Dates: March 17-18, 2026
  • Location: Virtual

About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph^TM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders. For more information, please visit www.seaporttx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260218422769/en/